Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
暂无分享,去创建一个
P. Kostenuik | M. Stolina | E. Douni | N. Bonnet | S. Ferrari | R. Dacquin | P. Jurdic | Vagelis Rinotas | A. Niti | Chun-Ya E Han | V. Rinotas
[1] H. Takayanagi,et al. Osteocyte control of osteoclastogenesis. , 2013, Bone.
[2] A. Villa,et al. RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease , 2013, Clinical & developmental immunology.
[3] P. Kostenuik,et al. Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL‐dependent ARO , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] Xinquan Wang,et al. Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin , 2012, The Journal of Immunology.
[5] A. Munnich,et al. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. , 2012, Human molecular genetics.
[6] George Kollias,et al. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. , 2012, Human molecular genetics.
[7] Ian Pyrah,et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. , 2011, Bone.
[8] P. Kostenuik,et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. , 2011, Bone.
[9] Xiaojuan Li,et al. Quantification of vertebral bone marrow fat content using 3 tesla MR spectroscopy: Reproducibility, vertebral variation, and applications in osteoporosis , 2011, Journal of magnetic resonance imaging : JMRI.
[10] J. Penninger,et al. RANKL/RANK—beyond bones , 2011, Journal of Molecular Medicine.
[11] R. Effros,et al. PKA-induced Receptor Activator of NF-κB Ligand (RANKL) Expression in Vascular Cells Mediates Osteoclastogenesis but Not Matrix Calcification* , 2010, The Journal of Biological Chemistry.
[12] C. O’Brien. Control of RANKL gene expression. , 2010, Bone.
[13] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[14] P. Kostenuik,et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. , 2009, Bone.
[15] F. Saad,et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.
[16] P. Kostenuik,et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. , 2009, The American journal of pathology.
[17] A. Klibanski,et al. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. , 2009, The American journal of medicine.
[18] T. Saunders,et al. Generating transgenic mice from bacterial artificial chromosomes: transgenesis efficiency, integration and expression outcomes , 2009, Transgenic Research.
[19] P. Kostenuik,et al. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] J. Penninger,et al. RANK/RANKL: Regulators of Immune Responses and Bone Physiology , 2008, Annals of the New York Academy of Sciences.
[21] Andrei L. Turinsky,et al. Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft. , 2007, Bone.
[22] Hong Yang,et al. Downregulation of beta-catenin and transdifferentiation of human osteoblasts to adipocytes under estrogen deficiency , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[23] M. Bouxsein,et al. Ovariectomy‐Induced Bone Loss Varies Among Inbred Strains of Mice , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] C. Laplace,et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.
[25] D. Lacey,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.
[26] H. Yasuda,et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.
[27] E. Wagner,et al. Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.
[28] Yongwon Choi,et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] D L Lacey,et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.
[30] T. Martin,et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.
[31] Yongwon Choi,et al. TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.
[32] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[33] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[34] A. Darby. BONE FORMATION AND RESORPTION IN POSTMENOPAUSAL OSTEOPOROSIS , 1981, The Lancet.
[35] Mary L Bouxsein,et al. Mechanisms of Disease: is osteoporosis the obesity of bone? , 2006, Nature Clinical Practice Rheumatology.
[36] S. Hagl,et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. , 2004, Journal of molecular and cellular cardiology.
[37] G. Kollias,et al. Genetic engineering in the mouse: tuning TNF/TNFR expression. , 2004, Methods in molecular medicine.
[38] G. Kollias,et al. Genetic Engineering in the Mouse , 2004 .